Loading...

CGTX COGNITION THERAPEUTICS INC US FDA Inspections 8-K Filing

CGNT

CGTX

COGNITION THERAPEUTICS INC

(CGTX)

2025 8-K

Show Summary

Summary

Financial Statements

Market Expansion

Clinical Trials

Financial Statements

Financial Results

Nasdaq Notification

Investor Presentation

Investor Presentation

Study Data Release

Financial Results

Investor Presentation

Nasdaq Deficiency Notice

Investor Presentation

Financial Results Announcement

Annual Meeting Voting Results

Financial Results Announcement

Financial Results Announcement

Public Offering

Financial Results

Grant of Performance Restri...

Investor Presentation

Financial Results Announcement

Exhibit Attached

Regulation FD Disclosure

Financial Results Announcement

Phase 2 Study Results

Annual Meeting of Stockholders

Financial Results Announcement

Appointment of CFO

Regulation FD Disclosure

Financial Results Announcement

FDA Clearance for CT1812 Dr...

Regulation FD Disclosure

Purchase Agreement with Lin...

FDA Clearance for Phase 2 S...

FDA Clearance for CT1812

External Links:

On May 8, 2025, Cognition Therapeutics, Inc. announced the topline results from its Phase 2 clinical trial, COG2201, for zervimesine aimed at treating geographic atrophy due to dry age-related macular degeneration.

AI Assistant

COGNITION THERAPEUTICS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.